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Abstract
Background: Late diagnosis is an important cause of HIV-related morbidity, mortality and healthcare costs in the
UK and undiagnosed infection limits efforts to reduce transmission. National guidelines provide recommendations
to increase HIV testing in all healthcare settings. We evaluated progress towards these recommendations by
comparing missed opportunities for HIV testing and late diagnosis in two six year cohorts from North East
Scotland.
Methods: We reviewed diagnostic pathways of all patients newly diagnosed with HIV referred to infectious
diseases and genito-urinary medicine services between 1995 and 2000 (n = 48) and 2004 to 2009 (n = 117). Missed
presentations (failure to diagnose ≤ 1 month of a clinical or non-clinical indicator for testing), late diagnosis (CD4 <
350 cells/mm
3), and time to diagnosis (months from first presentation to diagnosis) were compared between
cohorts using c
2 and log-rank tests. Determinants of missed presentation were explored by multivariate logistic
regression. Breslow-Day tests assessed change in diagnostic performance by patient subgroup.
Results: There were significant decreases in missed presentations (33% to 17%; P = 0.02) and time to diagnosis
(mean 17 months to 4 months; P = 0.005) but not in late diagnosis (56% vs. 60%; P = 0.57) between earlier and
later cohorts. In the later cohort patients were significantly more likely to have acquired HIV abroad and presented
with early HIV disease, and testing was more likely to be indicated by transmission risk or contact with GUM
services than by clinical presentation. Missed presentation remained significantly less likely in the later cohort (OR =
0.28, 95% CI 0.11 to 0.72; P = 0.008) after adjustment for age, transmission risks and number of clinical indicators.
Reductions in missed presentation were greater in patients < 40 years, of non-UK origin, living in least deprived
neighbourhoods and with early disease at presentation (P < 0.05). 27% of missed presentations occurred in primary
care and 46% in general secondary care.
Conclusions: While early diagnosis has improved in epidemiological risk groups, clinical indications for HIV testing
continue to be missed, particularly in patients who are older, of UK origin and from more deprived communities.
Increasing testing in non-specialist services is a priority.
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Background
Diagnosis is a critical limiting factor in the treatment
and control of HIV/AIDS worldwide. Globally, up to
9 0 %o fp e o p l el i v i n gw i t hH I Vm a yb eu n a w a r eo ft h e i r
status [1]: with estimates ranging from 21% to 30% in
developed nations [2,3]. In the context of a maturing
pandemic, there has been a shift in attitudes towards
testing, from an emphasis on protection of civil rights to
improving public health, matched by models of provider,
rather than patient, initiated testing [4]. Effectiveness of
strategies for increasing testing and diagnosis is depen-
dent upon regional epidemic status [1], but responses
have been varied even within areas of low-HIV preva-
lence. Many countries, including the USA and Canada
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general healthcare settings.
In the UK 25% of HIV infections are undiagnosed,
undermining efforts to reduce transmission [5], and late
diagnosis is an important cause of HIV-related morbid-
ity [6], mortality [7] and healthcare costs [8]. A national
audit of deaths among HIV infected adults found that
late diagnosis was the leading remediable cause of HIV-
related death [7]. The responsibilities of all health work-
ers and services in reducing the diagnosis gap has been
emphasised by leaders across disciplines [9]. In 2008
National guidelines for HIV testing were updated with
the aim of increasing HIV testing in all healthcare set-
tings [10]. Despite evidence of cost-effectiveness in low
prevalence areas [11], routine ‘opt-out’ testing was not
recommended, except in areas with adult prevalence >
0.2%. Instead, testing is to be offered universally in
selected services, to those with epidemiologic risk-fac-
tors and to children or adults presenting with one or
more prescribed clinical indicator diseases.
Beyond national surveillance [12], there is a need to
describe progress towards national standards for testing
and patterns in under-diagnosis at a regional level.
Demographic changes in the local HIV population
affected trends in missed acute HIV presentations in a
study from Liverpool [13]. Increased testing has been
associated with reductions in undiagnosed HIV infec-
tions in gay men in Scotland [14], but trends in diagno-
sis outside of high-risk groups are largely unknown.
This study compared the diagnostic pathways of HIV
positive patients in North East Scotland diagnosed
within two cohorts over a 15 year period, with the aim
of describing trends in missed HIV presentations, late
diagnosis and time-delay to diagnosis and associated
risk-factors.
Methods
Study design and setting
Aberdeen Royal Infirmary (ARI) is a tertiary referral
centre and acute teaching hospital, serving a population
of 500,000 in the North East of Scotland (NHS Gram-
pian). Outpatient HIV care is jointly provided by genito-
urinary medicine (GUM) and infectious disease (ID)
departments, with inpatient care in ARIs regional infec-
tious diseases unit. Shared provision started in 1999,
prior to which all patients were cared for by infectious
disease specialists although HIV testing, including anon-
ymous testing, took place in GUM throughout both
time periods.
This comparative retrospective cohort study
contrasted the diagnostic pathways of patients newly
diagnosed with HIV and referred to GUM or ID depart-
ments at ARI between 1995 and 2000 (n = 48) with
those diagnosed between 2004 and 2009 (n = 117).
Definitions
Recommendations from the BHIVA guidelines (2008)
were used to define clinical (presentations and haemato-
logical abnormalities) and non-clinical (service and epi-
demiological risk-groups) indicators for testing. First
case-note or laboratory system record of any indicator
was taken to be the first presentation. Declarations of
past transmission risks or serological evidence of past
infection, without prior documentation, were considered
as presentations at time of recording.
The primary outcome was ‘missed presentation’,
defined as failure to diagnose HIV within one month of
a clinical or non-clinical indicator for testing. Secondary
outcomes included, ‘late’ diagnosis (CD4 count < 350/
mm
3 at diagnosis), ‘very late’ diagnosis (CD4 count <
200/mm
3 at diagnosis) and time to diagnosis (months
from first presentation to diagnosis).
HIV clinical staging, and clinical diagnosis of AIDS, at
first presentation and diagnosis were defined by World
Health Organisation (WHO) criteria [15]. Patient post-
code was linked to neighbourhood (small-area) Scottish
Index of Multiple Deprivation (SIMD) decile and quin-
tile [16] to provide a proxy for socio-economic status
[17,18].
Study population and data collection
All patients > 18 years of age, newly diagnosed with
HIV and referred to infectious disease and GUM ser-
vices in ARI within the two time periods were identified
by anonymised-linked clinic records, patient manage-
ment systems and notes of current or deceased patients.
Patients moving outside of region were excluded as
detailed clinical records were not available. Routinely
collected data in case-notes from secondary care and
electronic laboratory records were reviewed for each
patient from earliest documented clinical or non-clinical
indication for HIV testing (first presentation) to actual
diagnosis. All presentations were documented up to
point of diagnosis. Presentations to primary care were
considered only where accompanied by documentation
in electronic summaries from the patient’s general prac-
titioner (GP). Such summaries are typically provided on
r e f e r r a lt o ,o ro nr e q u e s tf r o m ,s e c o n d a r yc a r ei nt h e
region.
Research carried out was in compliance with section
25 of the Helsinki Declaration [19]. Permission to access
medical notes was granted by the Clinical Effectiveness
Facilitator from Aberdeen Royal Infirmary’s Medical
Records Department (Project ID: 2035).
Data analysis
Frequency of missed presentation, late and very late
diagnosis and time-delay to diagnosis were compared
between the six-year cohorts using Fisher’s exact and
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testing at first presentation were compared using Fish-
er’s exact or Mann-Whitney U tests. Risk factors for
missed presentation were explored via univariate and
multivariate logistic regression. Cohort (time period)
was included as an ap r i o r ideterminant and other cov-
ariates were entered into a multivariate model if P <
0.10 in univariate analysis. Breslow-Day tests were used
to investigate heterogeneity in rates of missed presenta-
tion in later versus earlier cohorts across patient sub-
groups. Further comparison of time to diagnosis
between cohorts was made using Kaplan-Meier curves
and multivariate Cox-regression adjusting for case-mix.
Finally, in patients with a missed presentation we
assessed disease progression by time of diagnosis by
comparing the number of clinical indicators for testing,
clinical stage and presence or absence of AIDS defining
illness at first presentation and diagnosis using related-
samples Wilcoxon-signed rank tests. Likelihood of
immunologically advanced disease (CD4 < 200 cells/
mm
3) at diagnosis was compared between patients with
and without missed presentation by logistic regression
adjusting for baseline characteristics.
Results
Cohort characteristics
Compared with the earlier cohort, patients diagnosed
between 2004 and 2009 were significantly more likely to
have acquired HIV from outside the UK (59% vs. 37%; P
= 0.01), be from less-deprived neighbourhoods and pre-
sent with seroconversion illness or early HIV disease,
despite comparable CD4 counts at diagnosis (Table 1).
Primary outcomes
Overall, 22% of diagnoses were preceded by at least one
missed presentation (n = 36). Frequency of late and very
late diagnosis were 57% and 40% respectively and mean
time to diagnosis was 8 months (95% CI: 4 to 12
months). There were significant decreases in missed
presentations (33% to 17%; P =0 . 0 2 )a n dt i m et od i a g -
nosis (mean 17 months to 4 months; P = 0.005) between
earlier and later cohorts, but not in frequencies of late
(56% vs. 61%; P = 0.57) or very late (39% vs. 44%; P =
0.53) diagnosis.
Indicators for testing at first presentation
Patients in the later cohort were less likely to present
with a clinical indicator disease (63% vs. 88%; P = 0.005)
and more likely to present with epidemiological risk fac-
tors or via a service applying universal testing (Table 2).
The higher proportion of patients acquiring HIV in
high-risk regions (HIV prevalence > 1%) and increased
contact with GUM services largely explained these
trends. Significantly fewer first presentations with
candidiasis (19% to 8%; P = 0.04) and bacterial pneumo-
nia (8% to 2%; P = 0.04) were observed in the later
cohort, otherwise clinical presentations were broadly
comparable between the two cohorts (P > 0.10 for all)
(Figure 1).
Missed presentations
Stratifying by clinical indicator disease (Figure 1), no
presentations with AIDS defining illness were missed
in either time period, whilst 8 of 9 blood dyscrasias
were missed. c
2 tests revealed a lower risk of missed
presentation with sexually transmitted infection (STI)
in the later cohort (13% vs. 50%; P = 0.02) and a non-
significant decline in missed seroconversion illness (0%
vs. 33%; P = 0.17). Presentations with pneumonia and
hepatitis B or C were persistently missed. In patients
not diagnosed at first presentation 13 (36%) had at
l e a s to n ef u r t h e rd o c u m e n t e dm i s s e dp r e s e n t a t i o n
before diagnosis. The majority of missed presentations
occurred in non-specialist hospital services (47%) or
primary care (27%), with 13% in GUM and 7% in
antenatal services.
Determinants of missed presentation
In univariate logistic regressions lower risks of missed
presentations were predicted by age < 40 yrs, origin in
high-risk regions, MSM, partner HIV positive, diagnosis
in the later cohort and higher number of indicators for
testing (Table 3). In a final multivariate model missed
presentation remained significantly less likely in the
later cohort (OR = 0.28, 95% CI 0.11 to 0.72; P =0 . 0 0 8 )
after adjustment for these covariates. IV drug use was
associated with a large, but non-significant increased
risk of missed presentation.
Stratifying by patient sub-group revealed a signifi-
cantly greater reduction in risk of missed presentation
in the later cohort amongst younger patients (< 40 yrs),
living in least-deprived neighbourhoods and presenting
with early or asymptomatic disease (Breslow-day tests; P
< 0.05) (Figure 2). Improved diagnosis was also noted in
those with a CD4 count > 200 at diagnosis, or from
high-risk areas, although differences within strata were
non-significant.
Time to diagnosis
Kaplan-Meier curves reflected a higher proportion of
diagnoses made at first presentation in the later cohort
as well as reduced time to diagnosis in those missed at
first presentation (median delay 10 vs. 34 months; p =
0.005) (Figure 3). A multivariate Cox-regression model
revealed a non-significant improvement in rate of (time
to) diagnosis (adjusted HR = 1.36, 95% CI: 0.96 to 1.94;
P = 0.084) after adjusting for case-mix: the proportion
of patients diagnosed within one year of first
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the later cohort.
Associations between missed presentation and disease
progression
In those patients with a missed presentation (n = 36),
the median number of clinical indicator diseases
increased significantly from 1 at first presentation to 3
at diagnosis (Related-samples Wilcoxon-Signed rank
tests, P < 0.001). Progression to AIDS (25%) or higher
WHO clinical staging (53%) was common between
missed presentation and diagnosis. Compared with
those diagnosed at first presentation, patients with ≥ 1
missed presentation were also substantially more likely
to have immunologically advanced disease (CD4 < 200
cells/mm
3) at diagnosis: 74% vs. 30% (OR = 6.9, 95% CI:
3.0 to 16.2; P < 0.001).
Discussion
This study looked for evidence of improvements in early
HIV diagnosis in response to national strategies to
increase testing in all healthcare settings. Diagnostic
pathways were compared in two cohorts of newly diag-
nosed HIV patients from a 15 year period in North East
Table 1 Demographic and clinical characteristics by cohort
All
n = 165
1995-2000
n=4 8
2004-2009
n = 117
P value
Gender (female) 47 (29%) 10 (21%) 37 (32%) 0.163
Age, years 38 (10) 38 (9) 38 (11) 0.810
SIMD
†, quntile 0.040
1 (most deprived) 24 (15%) 10 (21%) 14 (13%)
2 22 (14%) 8 (17%) 13 (13%)
3 38 (24%) 13 (27%) 25 (22%)
4 38 (24%) 9 (19%) 29 (26%)
5 (least deprived) 38 (24%) 8 (17%) 30 (27%)
Origin 0.226
UK 108 (66%) 36 (75%) 72 (62%)
sub-Saharan Africa 39 (24%) 9 (19%) 30 (26%)
Other 18 (11%) 3 (6%) 15 (13%)
Area of presumed acquisition 0.026
UK 78 (47%) 30 (63%) 48 (41%)
Europe 10 (6%) 2 (4%) 8 (7%)
sub-Saharan Africa 58 (35%) 14 (29%) 44 (38%)
Asia/SE Asia 19 (12%) 2 (4%) 17 (15%)
UK origin acquired in high-risk area. 26 (16%) 6 (12%) 20 (17%)
Previous (negative) HIV test 51 (31%) 13 (27%) 38 (33%) 0.469
Months since last HIV test (if occurred) 41 (42) 29 (20) 45 (47) 0.090
Clinical staging at first presentation (WHO) 0.010
Primary HIV infection 3 (2%) 0 (0%) 3 (3%)
Stage 1 102 (62%) 23 (48%) 79 (68%)
Stage 2 11 (7%) 5 (10%) 6 (5%)
Stage 3 24 (15%) 9 (18%) 15 (13%)
Stage 4 25 (15%) 11 (23%) 14 (12%)
Clinical staging at diagnosis (WHO) 0.002
Primary infection 2 (1%) 0 (0%) 2 (2%)
Stage 1 84 (51%) 14 (30%) 70 (60%)
Stage 2 12 (7%) 6 (13%) 6 (5%)
Stage 3 29 (18%) 14 (29%) 15 (13%)
Stage 4 38 (23%) 14 (29%) 24 (21%)
Cd4 count at diagnosis (cells/mm
3) 0.517
< 200 66 (40%) 21 (44%) 45 (39%)
200-350 28 (17%) 8 (17%) 20 (17%)
> 350 71 (43%) 19 (40%) 52 (44%)
* c
2 test of difference in proportion missed, P = 0.02. Otherwise non-significant.
† Scottish Index of Multiple Deprivation.
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missed presentations and time to diagnosis between the
two time periods. However, patient groups, clinical pre-
sentations, and services in which opportunities for early
diagnosis continue to be missed were also identified.
Delay to diagnosis and missed presentation were
strongly associated with disease progression at time of
diagnosis.
As reported elsewhere in the UK [13], changes in
socio-demographics of the HIV population had impor-
tant impacts upon first presentations. We noted
increases in patients from, or acquiring HIV in, regions
of high HIV prevalence, and living in less deprived
neighbourhoods. In North East Scotland these trends
are related since contact with hyperendemic regions is
largely related to a mobile labour-force in the oil indus-
try [20]. An important minority diagnosed in occupa-
tional health screening emphasises the importance of
HIV care for workers in globalised industries [21].
Patient ethnicity is an important epidemiological risk
factor that should be recorded at first contact with all
UK healthcare services [10]. Substantial reductions in
missed presentations in those acquiring HIV in high-
risk regions, suggested increased awareness of transmis-
sion risks, while patient factors, including access to
alternative health insurance, may explain discordance
with findings of barriers to diagnosis for some migrant
populations [22].
Our findings also warn against stereotyping the ‘at
risk’ patient [23]: 20% of diagnoses occurred in those
without transmission risks. Missed presentations per-
sisted in patients who were older, of UK origin and
from more deprived communities. Delayed HIV diag-
nosis in older patients is common [13,23] and of
national importance. Across the UK the proportion of
new diagnoses made in those > 40 years increased
from 23% to 38% between 1995 and 2009[24] and
older age predicts poorer outcomes from anti-retroviral
therapy, particularly for immunologically advanced dis-
ease [25]. Overemphasis on ethnicity, without refer-
ence to contextual factors such as deprivation and
social networks, impair effective prevention of other
infectious diseases including sexually STIs [26] and
tuberculosis [27]. Regional patterns in transmission
risks may be of more importance to clinicians than
national epidemiology. A high proportion of heterosex-
ual and IVDU transmission amongst those of UK ori-
gin has been noted in the North East of Scotland [20].
Under-diagnosis in IVDUs may be particularly impor-
tant given associations with high-risk sexual behaviours
[28] and TB transmission [29].
In common with a study of acute HIV presentations
from Liverpool [13], we found consistent patterns of
all presentations in both cohorts. Despite this we
found limited evidence that strategies to increase HIV
diagnosis have improved our ability to recognise early
clinical indicators in the absence of epidemiological
risk-factors. In particular, unexplained haematological
abnormalities, bacterial pneumonias and viral hepati-
tis frequently failed to prompt HIV testing. This may
Table 2 Summary of indicators for HIV Testing at first presentation
All
n = 165
1995-2000
n=4 8
2004-2009
n = 117
P value
Summary
Median no. clinical indicators 1 (0-2) 1 (1-2) 1 (0-1) 0.002
Median number of all non-clinical indicators 2 (1-2) 1 (1-2) 2 (1-3) < 0.001
Median number of all clinical & non-clinical indicators 3 (2-4) 3 (2-4) 3 (2-4) 0.697
Services indicator (any) 102 (62%) 19 (40%) 83 (71%) < 0.001
Ante-natal/ToP 14 (9%) 4 (8%) 10 (9%) 0.964
GUM 61 (37%) 8 (17%) 53 (45%) 0.001
TB, Hep B/C, lymphoma 27 (16%) 8 (17%) 19 (16%) 0.964
Occupational health or screening* 11 (7%) 3 (6%) 8 (7%) 0.891
Transmission risk indicator (any) 132 (80%) 33 (69%) 99 (85%) 0.021
Country of origin high prevalence (> 1%) 53 (32%) 10 (21%) 43 (37%) 0.047
Men with disclosed sexual contact with men (MSM) 46 (28%) 14 (29%) 32 (27%) 0.813
IVDU 8 (5%) 2 (4%) 6 (5%) 0.794
Sexual contact abroad 42 (26%) 10 (21%) 32 (28%) 0.383
Partner HIV+ 24 (15%) 6 (13%) 18 (15%) 0.633
Blood donors, dialysis patients or organ donors/recipients 6 (4%) 4 (8%) 2 (2%) 0.039
Non-clinical indicator (any transmission risk or service indicator) 147 (89%) 37 (77%) 110 (94%) 0.002
Clinical Indicator diseases (any) 119 (72%) 42 (88%) 74 (63%) 0.005
Indicators as recommended by national guidelines for HIV testing, except *.
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M issing / 
presentations 
(% )
M issing / 
presentations 
(% )
AIDS Defining condition
0 / 1 (0%) TB 0 / 2 (0%)
0 / 5 (0%) PCP 0 / 6 (0%)
0 / 1 (0%) Cerebral toxoplasmosis 0 / 2 (0%)
0 / 2 (0%) Kaposi's sarcoma 0 / 2 (0%)
0 / 1 (0%) CMV retinitis 0 / 1 (0%)
Respiratory
3 / 4 (75%) Bacterial Pneumonia 1/2 (50%)
Neurology
0 / 1 (0%) Peripheral neuropathy 0 / 0 (0%)
Dermatology
0 / 2 (0%) Seborrhoeic dermatitis (severe or recalcitrant) 1/5 (20%)
1 / 2 (50%) Psoriasis (severe or recalcitrant) 0/1 (100%)
0 / 2 (0%) Multidermatomal or recurrent herpes zoster 1/5 (80%)
Gastroenterology
1 / 9 (11%) Oral candidiasis 2 / 9 (11%)
0 / 4 (0%) Oral hairy leukoplakia 0 / 4 (0%)
0 /0 (0%) Chronic diarrhoea of unknown cause 1 / 3 (33%)
1 / 8 (13%) Weight loss of unknown cause 1 / 10 (10%)
0 / 4 (0%) Hep B infection 2 / 9 (11%)
1 /  2 (50%) Hep C infection 3 / 6 (50%)
Gynaecology
2 / 2 (100%) VIN or CIN II+ 0 / 1 (0%)
Opthalmology
0 / 2 (0%) Infective retinal disease* 0 / 2 (0%)
Other
1 / 2 (50%) Lymphadenopathy of unknown cause 1 / 6 (16%)
2 / 6 (33%) Mononucleosis like illness 0 / 8  (0%)
0 / 0 (0%) PUO 1 / 6 (16%)
4 / 8 (50%) STI 4 / 30 ( 13%)
Haematology
3 / 4 (75%) Thrombocytopenia 3 / 3 (100%)
0 / 0 (0%) Lymphopenia 1 / 1 (100%)
0 / 0 (0%) Neutropenia 1 / 1 (100%)
1995  to 2000 2004  to 2009
Figure 1 Missed and diagnosed clinical presentations as percentage of total cohort.
Table 3 Risk-factors for missed presentation by univariate and multivariate logistic regression
Univariate Regression Multivariate Regression
OR (95% CI) P value OR (95% CI) P value
Time period (later) 0.41 (0.19 to 0.89) 0.024 0.28 (0.11 to 0.72) 0.008
Age, per 10 years 1.79 (1.20 to 2.55) 0.004 1.69 (1.09 to 2.64) 0.007
Transmission risk:
Country of origin high prevalence 0.35 (0.14 to 0.90) 0.029 0.39 (0.12 to 1.21) 0.103
MSM 0.45 (0.17 to 1.15) 0.097 0.30 (0.10 to 0.88) 0.028
IVDU 3.91 (0.92 to 16.5) 0.064 4.32 (0.82 to 23.0) 0.086
Partner HIV+ 0.13 (0.02 to 1.01) 0.051 0.09 (0.01 to 0.81) 0.032
Any Service indicator 0.54 (0.25 to 1.03) 0.100 -
†
Number of clinical indicators 0.86 (0.62 to 1.20) 0.376 0.60 (0.37 to 0.97) 0.032
Number of non-clinical indicators 0.49 (0.32 to 0.75) 0.001 -*
Number of all indicators 0.63 (0.46 to 0.87) 0.006 -*
* Excluded as co-linearity with individual non-clinical or clinical indicators
† Inclusion did not improve model fit.
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specialist services and immunocompetent patients.
HIV related thrombocytopenia is common and not
isolated to disease stage or risk group but is rarely
profound or symptomatic [30]. Hepatitis C acquisition
m a yb eh i g h e s ta r o u n dt h et i m eo fp r i m a r yH I V
infection [31]. Automatic flags for HIV testing on
laboratory reports may help clinicians identify these
presentations. Non-specificity of early HIV presenta-
tions remains a clinical challenge: while all AIDS
defining illnesses prompted immediate diagnosis, we
identified several commonly missed clinical indicators
including, recurrent herpes zoster [32] oral candidia-
sis [33] and weight loss. By contrast recognition of
primary HIV infection was better than reported else-
where in the UK [34].
Odds of missed presentation in 
1995-2000 versus 2004 -2009
No 
Difference
Excess in 
2004-2009
Excess in 
1995-2000
Number
1995-2000 2004-2009
Gender
Female 47 4 (40%) 5 (14%)
Male 118 12 (32%) 15 (19%)
Age group*
15-40 105 12 (40%) 7 (9%)
>40 61 4 (22%) 13 (31%)
Socioeconomic status*
SIMD decile 0-5 72 7 (29%) 9 (19%)
SIMD decile 6-10 93 9 (38%) 11 (16%)
Country of origin
UK 108 11 (31%) 16 (22%)
sSA 39 3 (33%) 1 (3%)
Other 18 2 (67%) 3 (20%)
Previous HIV testing
No 114 12 (34%) 16 (20%)
Ye s 51 4 (31% ) 4 (11% )
T ransmission risks
High-risk area 53 3 (30%) 3 (7%)
Contact high-risk area 42 3 (30%) 4 (13%)
MSM 46 2 (14% ) 4 (13% )
HIV  stage at presentation*
HIV seroconversion 3 0 (0%) 0 (0%)
Stage I 102 11 (48%) 10 (13%)
Stage 2 11 1 (20%) 2 (33%)
Stage 3 24 4 (44%) 5 (33%)
Stage 4 25 0 (0%) 3 (22%)
CD4+ at diagnosis
< 200 66 10 (48%) 17 (38%)
> 200 99 6 (22%) 3 (4%)
Overall estimate
 No (%) missed
†
†
Figure 2 Risk of missed presentation by time period stratified by clinical and epidemiological risk factors. * Breslow-Day test of
homogeneity of variance: P < 0.05 suggesting significant heterogeneity within the strata.
† Not calculable due to small numbers. Transmission
risks of IVDU, partner HIV positive, recipients of blood products/organs or dialysis patients were not calculated due to small numbers.
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sentations were noted in both specialist and non-specia-
list services. Universal screening in services specified by
national guidelines would have captured only 62% of
new diagnoses and frequency of multiple missed presen-
tations suggest need for improved HIV awareness at all
care levels. The 27% of missed presentations identified
in primary care supports emphasis on improving diag-
nosis in this setting [22]. A marked increase in contact
with GUM services explains a significant improvement
in diagnosis following an STI. The GUM model of care
with anonymised records, drop-in facility and routine
HIV testing may offer significant advantages in early
HIV diagnosis, particularly if planned integration with
primary care is realised [36].
The association of missed presentation and delay to
diagnosis with immunological and clinical disease pro-
gression is well documented [37]. It is encouraging to
note that the median time delay from missed presenta-
tion to diagnosis had fallen by 24 months between the
first and second cohort. The disparity between reduc-
tions in missed presentation and non-significant decline
in late or very late diagnosis may reflect shifts in demo-
graphics of all patients. In particular under-diagnosis
and lack of documented health contact outside the UK
create challenges to detection of HIV in migrants.
Debate around the cost-effectiveness and practicability
of universal ‘opt-out’ testing continues in the UK [38].
However our findings suggest that opportunistic testing
presents considerable challenges to clinicians and public
health. When opportunities to prevent transmission are
added to those of improved survival after early diagno-
sis, the argument for routine HIV surveillance is persua-
sive [11,38].
The generalisability of findings from this study may be
limited by regional differences in HIV populations, test-
ing and care provision arrangements. However, we
believe the study highlights important challenges in
opportunistic testing relevant to UK and similar health-
care settings. Limits to the internal validity of our find-
ings arise from a retrospective design reliant upon
records in secondary care. It was not possible to identify
or include patients lost to follow up, or relocating out of
area. A previous study of new HIV diagnoses between
1985 and 1997 suggest over representation of those of
non-UK origin, students and prisoners in those disconti-
nuing care within region [20]. Incomplete documenta-
tion in case-notes may mean failure to capture all
relevant presentations or risk factors. However, systema-
tic bias was minimised by a standardised data collection
method for all patients with independent assessments of
relevance of presentations by two investigators. Presen-
tations in primary care were identified from printed
summaries or documentations in case-notes from sec-
ondary care only, and may be under-represented. Inves-
tigation of missed presentations in this setting is an
important priority [22]. Without concurrent control it is
not possible to attribute trends in missed presentation
to national strategies to improve HIV diagnosis [39].
Indeed our study suggests most improvements relate to
changes in patient demographics and service provision.
Further prospective, cluster randomised controlled trials
of interventions to improve HIV diagnosis in general
healthcare settings are required.
Conclusions
Early diagnosis of HIV infection is a priority in HIV-
related healthcare, but is complicated by changing
socio-demographics of HIV populations in the UK. A
significant reduction in missed presentations in North
East Scotland was attributable to increased recognition
of epidemiological risk-factors and contact with GUM
services, rather than improvements in opportunistic
testing of patients with clinical indicators. Conse-
quently, missed opportunities for early diagnosis per-
sist in populations considered at lower risk and
presenting to non-specialist services. Diagnosis in
those with haematological abnormalities or other
blood-borne viruses might be improved by including
advice on HIV testing in laboratory reports. However,
evidence of disease progression after missed presenta-
tion further suggests the need to reconsider routine
‘opt-out’ testing in all general healthcare settings to
reduce delays to HIV diagnosis.
Figure 3 Kaplan-Meier curves of time to diagnosis from first
presentation by cohort. (Log-rank test, P = 0.005).
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